Editorial Board Members
Nick Barlev, Saint Petersberg
Nick Barlev has obtained his joined PhD degree from Kazan State University, Russia and University of Aarhus, Denmark. He carried out his postdoctural training on molecular mechanisms of transcription regulation in the laboratory of Dr. Shelley L. Berger at the Wistar Institute, Philadelphia. He joined Tufts University, Boston in 2002 as an Assistant Professor to work on the role of lysine-specific post-translational covalent modifications in regulation of tumor supressor p53. In 2008 he moved to the University of Leicester, UK where his lab worked on various aspects of lysine methylation in p53, E2F1 and other critical transcriptional regulators. In 2015 Dr Barlev became the Head of Gene Expression Regulation Unit in the Institute of Cytology, Saint Petersberg, Russia. His team investigates the role of p53 as a gene expression regulator, lysine-specific methylation in tumor suppression/progression, DNA Damage response, and control of protein translation by proteasome-mediated degradation.
Isaac Harris, Boston
Isaac S. Harris is a Postdoctural Research Fellow in the Department of Cell Biology at Harvard Medical School (HMS) in Boston, USA. Isaac completed his PhD in 2013 under the supervision of Tak W. Mak at Princess Margaret Hospital in Toronto, Canada. During this time, he developed a core foundation in translational research, including an expertise in mouse models of cancer. Isaac focused his efforts on investigating cancer metabolism, specifically the role of antioxidants in tumorigenesis. His work demonstrated the importance of glutathione and thioredoxin antioxidant pathways in tumor initiation and progression. Following his PhD, Isaac moved to Boston to begin a fellowship in the lab of Joan Brugge at HMS. While maintaining a focus on antioxidants, he has expanded his research to investigate novel therapeutic strategies for cancer. Through the development of high-throughput assays, Isaac has been able to investigate the interconnectivity of antioxidants with functional profiling of different cellular states of cancer.
Richard Killick, London
Richard Killick is a molecular neurobiologist, principal investigator and lecturer at King's College London, UK. Dr. Killick received his D.Phil. from Sussex University in 1994 following his investigations of molecular components forming the avian and mammalian auditory systems. He continued his career as a postdoctoral investigator at Sussex examining the developmental neurobiology of genes and proteins involved in Alzheimer's disease, within the inner ear. In 1999 he moved to King's College London, joining the Neuroscience department to further his investigations into the underlying cause of Alzheimer's disease and other neurodegenerative/neurological disorders. During this time his attention focused on cellular signaling pathways that underpin the neuropathology of Alzheimer's disease, particularly the Wingless/Wnt, Notch and Insulin pathways. In 2010 he established his own group at KCL and his current focus is on the role of the Wnt-Planar Cell Polarity pathway in Alzheimer's disease neuropathology and the central role pf p53 in the activation of this pathway by b-amyloid. His group have recently moved to the new, purpose built Maurice Wohl Clinical Neuroscience Institute. There he collaborates closely with a range of other neuroscientists, clinicians and structural biologists and is also involved in biomarker discovery and drug discovery programmes.
Inna Lavrik, Magdeburg
Professor Inna N. Lavrik heads the Translational Inflammation Research laboratory at the Medical Faculty of the Otto von Guericke University in Magdeburg, Germany. She completed her PhD studies at the Lomonosov Moscow State University and the Max Planck Institute of Molecular Genetics in Berlin, Germany. In 2000, she became a Postdoctoral Fellow investigating death receptor signaling networks in the Division of Immunogenetics at the German Cancer Research Center headed by Prof. Peter H. Krammer. In 2008, she joined Bioquant Systems Biology Center in Heidelberg as a group leader focusing on bio-computational studies of apoptosis. In 2012, she was appointed Professor in the Medical Faculty of the Otto von Guericke University in Magdeburg, Germany. Her current research includes the molecular mechanisms governing the function of macromolecular complexes in death receptor networks, their posttranslational modifications, and the computational modeling of apoptosis pathways.
Alessandro Rufini, Leicester
Alessandro Rufini got his degree at the University of Rome "La Sapienza", working in the laboratory of Prof. Antonio Fantoni. Then he did an internship at the laboratory of Molecular Oncogenesis under the supervision of Dr. Marco Crescenzi at the Institute Regina Elena in Rome, before being employed at the Department of Toxicology and Etoxicology at the "Instituto Superiore de Sanita" (ISS), Rome. From 2002 he worked as a PhD student in Professor Gerry Melino's laboratory at the University of Rome Tor Vergata. During this time his research focused on the p53-family of transcription factors and their involvement in development. He then joined Prof. Tak W. Mak's laboratory at Campbell Family Institute for Breast Cancer Research, at the Princess Margaret Hospital in Toronto in 2006 as post-doc and continued working on the p53-family. In 2009 he moved to join Professor Gerry Melino at the MRC Toxicology Unit in Leicester, UK, working as investigator scientist until he was appointed to his current position as lecturer in the Department of Cancer Studies at the University of Leicester in 2013. Currently, he leads a research group focused on early detection of disease and exploitation of metabolic pathways for prevention and therapy of colon cancer. He has authored numerous peer reviewed articles and is on the editorial board of Frontiers in Cancer Molecular Targets and Therapeutics and Cell Death Discovery, while acting as reviewer for several peer reviewed jorunals.
A Emre Sayan, Southampton
A. Emre Sayan is an Associate Professor of Cancer Biology and a Lecturer at the University of Southampton, UK. Dr. Sayan received his PhD in 2002 for his research on p53 family member, p73. He continued his career as he did 3 postdoctural studies in INSERM U370 (Paris, France), MRC Toxicology Unit (Leicester, UK) and University of Leicester (UK) working on different aspects of cancer such as apoptosis, cell cycle and epithelial-mesenchymal transition. During that time, he identified caspases cleaving p53 family member proteins (p53, p63 and p73), cell cycle is attenuated during epithelial-mesenchymal transition and metastatic cells become chemoresitant by interrupting phosphorylation events upstream of AMTATR and p53. In 2010 he established his lab in Southampton. His current work includes biomarker-drug discovery to identify and target metastatic carcinoma cells, breaking chemoresistance barrier by combination therapy and targeting tumour microenvironment. He has close collaborations with clinicians, uses in vitro-in vivo cancer models and performs in vivo imaging to supplement his research.